Arkansas Suspends Enforcement of Law Targeting Limited Drug Distribution Networks
Arkansas Board of Pharmacy voted to suspend enforcement of Act 630, a 2025 law restricting manufacturers’ limited drug distribution networks to favor in-state pharmacies. A federal court preliminarily enjoined enforcement against Novartis, citing likely unconstitutional discrimination under the Dormant Commerce Clause. After Bristol Myers Squibb sued and the AG said the act is likely unconstitutional, the Board authorized settlement and non-enforcement.
How this was made
The 30-second read
Why it matters
The Arkansas Board of Pharmacy voted to suspend enforcement after a federal court preliminarily enjoined enforcement against Novartis and after the Arkansas Attorney General indicated the Act is likely unconstitutional. The Board also authorized settlement discussions with entities that sued or threatened to sue, making the September 1, 2026 compliance deadline effectively moot for now.
Market read
For specialty drug manufacturers, the immediate Arkansas enforcement threat and fine exposure under Act 630 appear reduced, but litigation and possible legislative amendments keep the longer-term risk non-zero.
What to watch
The article does not quantify which specific Novartis products are covered, nor does it state whether settlement terms already remove all Arkansas-specific constraints for the broader manufacturer group.
Background
Arkansas Act 630 (enacted April 2025) restricted manufacturers’ ability to maintain limited prescription drug distribution networks, effectively requiring access for in-state pharmacies and tying compliance to Arkansas and public-plan payment.
Ticker impact
Novartis won a preliminary injunction against Arkansas Act 630, and the Board later voted to stop enforcing the law, reducing its compliance risk.
Modestly positive bias for NVS as the immediate threat of fines and network disruption in Arkansas is removed, though broader litigation outcomes remain.
The article ties the Board’s non-enforcement resolution to the Act being likely unconstitutional and references the Novartis injunction as the catalyst; however, it also notes no final judgments and potential legislative amendments.
Market effects
Highlights ongoing Dormant Commerce Clause vulnerability for state pharmacy-network restrictions, which can affect how specialty drug distribution and REMS-like networks are structured.
Arkansas Medicaid and state-plan payment leverage tied to Act 630 is neutralized by the Board’s non-enforcement resolution.
Reinforces a broader legal template that other states may face when using geography-based network mandates.
Counterpoint
Even with non-enforcement, the underlying lawsuits and potential legislative “cure” could reintroduce compliance uncertainty and delay any operational certainty for manufacturers.
Key entities
- regulatorArkansas Board of Pharmacy
Voted to suspend enforcement of Act 630 and authorized settlement discussions.
- companyNovartis
Obtained a preliminary injunction against Act 630 enforcement, which the Board cited as part of the non-enforcement posture.
- companyBristol Myers Squibb
Filed its own complaint and sought a preliminary injunction, alleging Act 630 would force changes to its specialty drug distribution.
- governmentArkansas Attorney General’s Office
Indicated after review that Act 630 is likely unconstitutional and supported settlement.
